HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Chagee Holdings - Some Points Worth the Attention

MIXUE Group (2097.HK) - Updates on Performance Forecast and Valuation Outlook

Pre-IPO Guming Holdings (PHIP Updates) - Some Points Worth the Attention

Pre-IPO MIXUE Group (2097.HK) - The IPO Is Attractively Priced

Pre-IPO MIXUE Group (PHIP Updates) - Some Points Worth the Attention

Equity Capital Markets

<ul>
<li>Chagee adopts the "1+1+9+N" business model, which ensures the successful replication of the single store model. However, we saw performance decline in 2024, and future performance growth sustainability is uncertain.</li>
<li>In terms of valuation, comparable companies include Starbucks and MIXUE. We think valuation of Chagee should be lower than MIXUE and Starbucks as both have proved themselves in the industry.</li>
<li>Future growth would inevitably slow down. Investors may need more 'safety margins' on valuation because despite short-term strong demand, investors need to be alert to the performance validation after IPO.  </li>
</ul>


Chagee adopts the "1+1+9+N" business model, which ensures the successful replication of the single store model. However, we saw performance decline in 2024, and future performance growth sustainability is uncertain.
In terms of valuation, comparable companies include Starbucks and MIXUE. We think valuation of Chagee should be lower than MIXUE and Starbucks as both have proved themselves in the industry.
Future growth would inevitably slow down. Investors may need more 'safety margins' on valuation because despite short-term strong demand, investors need to be alert to the performance validation after IPO.  


Sichuan Baicha Baidao Industrial (2555 HK)

Auntea Jenny (Shanghai) Industrial (AJI HK)

Pre-IPO Chagee Holdings - The Business Model, the Concerns Behind and Valuation Outlook